Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) Debt Ratio (2019 - 2024)

Historic Debt Ratio for Seres Therapeutics (MCRB) over the last 7 years, with Q2 2024 value amounting to 0.32.

  • Seres Therapeutics' Debt Ratio rose 2850.94% to 0.32 in Q2 2024 from the same period last year, while for Jun 2024 it was 0.32, marking a year-over-year increase of 2850.94%. This contributed to the annual value of 0.28 for FY2023, which is 9522.13% up from last year.
  • According to the latest figures from Q2 2024, Seres Therapeutics' Debt Ratio is 0.32, which was up 2850.94% from 0.3 recorded in Q1 2024.
  • Seres Therapeutics' 5-year Debt Ratio high stood at 0.32 for Q2 2024, and its period low was 0.04 during Q3 2021.
  • Over the past 5 years, Seres Therapeutics' median Debt Ratio value was 0.17 (recorded in 2022), while the average stood at 0.17.
  • As far as peak fluctuations go, Seres Therapeutics' Debt Ratio crashed by 7141.36% in 2021, and later soared by 30097.02% in 2022.
  • Over the past 5 years, Seres Therapeutics' Debt Ratio (Quarter) stood at 0.07 in 2020, then dropped by 3.34% to 0.07 in 2021, then soared by 108.87% to 0.15 in 2022, then surged by 95.22% to 0.28 in 2023, then grew by 12.5% to 0.32 in 2024.
  • Its Debt Ratio was 0.32 in Q2 2024, compared to 0.3 in Q1 2024 and 0.28 in Q4 2023.